Who are Latanoprost RATIOPHARM© latanoprost eyedrops's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Propess® (dinoprostone), Dinoprostone vaginal pessary.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/latanoprost-ratiopharm-latanoprost-eyedrops.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-18 · How we verify

Latanoprost RATIOPHARM© latanoprost eyedrops — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Latanoprost RATIOPHARM© latanoprost eyedrops (Latanoprost RATIOPHARM© latanoprost eyedrops) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Prostaglandin F2α analog. Area: Ophthalmology.

marketed Prostaglandin F2α analog Prostaglandin F (FP) receptor Ophthalmology Small molecule Live · refreshed every 30 min

Target snapshot

Latanoprost RATIOPHARM© latanoprost eyedrops (Latanoprost RATIOPHARM© latanoprost eyedrops) — University of Catanzaro. Latanoprost is a prostaglandin F2α analog that binds to prostaglandin F receptors in the eye to increase uveoscleral outflow of aqueous humor, thereby lowering intraocular pressure.

Comparator set (2 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Latanoprost RATIOPHARM© latanoprost eyedrops TARGET	Latanoprost RATIOPHARM© latanoprost eyedrops	University of Catanzaro	marketed	Prostaglandin F2α analog	Prostaglandin F (FP) receptor
Propess® (dinoprostone)	Propess® (dinoprostone)	University Hospital, Clermont-Ferrand	marketed	Prostaglandin F2α analog	Prostaglandin F receptor (FP receptor)
Dinoprostone vaginal pessary	Dinoprostone vaginal pessary	Università degli Studi di Brescia	marketed	Prostaglandin F2α analog	Prostaglandin F (FP) receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Prostaglandin F2α analog class)

University Hospital, Clermont-Ferrand · 1 drug in this class
University of Catanzaro · 1 drug in this class
Università degli Studi di Brescia · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Latanoprost RATIOPHARM© latanoprost eyedrops — Competitive Intelligence Brief. https://druglandscape.com/ci/latanoprost-ratiopharm-latanoprost-eyedrops. Accessed 2026-05-18.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab